| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
Saad Mark E is a Director at VTAK, with reported holdings spanning 2 companies. Recent filings cover 5 purchases and 4 sales. Those positions are worth an estimated $2.5M at current prices.
Our model assigns Saad Mark E a middling insider score of 50/100, based on 4 past trades. Over a 12-month horizon, 50.0% of those trades were profitable, with an average 12-month return of +9.5%.
Saad Mark E's largest disclosed position is in AXSM as Director, worth about $2.5M. The recent filings there lean toward selling, a net 50,920 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2025 | AXSM Axsome Therapeutics, Inc. | Director | Sale+OE | 37,577 | $165.18 | $6,206,968.86 | -65.3% | -7.5% | - | |
| Sep 5, 2025 | AXSM Axsome Therapeutics, Inc. | Director | Sale+OE | 9,127 | $125.07 | $1,141,513.89 | -47.7% | +18.3% | - | |
| Sep 11, 2024 | AXSM Axsome Therapeutics, Inc. | Director | Sale+OE | 11,016 | $91.31 | $1,005,870.96 | -52.4% | +8.6% | +35.1% | |
| Nov 17, 2021 | AXSM Axsome Therapeutics, Inc. | Director | Buy | 3,300 | $34.52 | $113,921.70 | +47.1% | -2.3% | +54.2% | |
| May 23, 2019 | AXSM Axsome Therapeutics, Inc. | Director | Buy | 3,500 | $22.33 | $78,155.00 | +99.9% | - | - |